“To increase access to cancer treatments across Europe, it is fundamental to make the best use of generic and biosimilar medicines,” Medicines for Europe has insisted in a new policy paper titled “Filling the gap: How off-patent medicines can improve the equity and quality of cancer care.”
Commenting on the launch of Medicines for Europe’s policy paper, the association’s president Christoph Stoller, who is also Teva’s general manager for Germany and Austria, said “cancer is one of the most burdensome health challenges of our time
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?